tiprankstipranks
Citius Pharmaceuticals Resubmits LYMPHIR™ License Application
Company Announcements

Citius Pharmaceuticals Resubmits LYMPHIR™ License Application

Citius Pharmaceuticals (CTXR) has released an update.

Citius Pharmaceuticals, Inc. has announced the resubmission of its Biologics License Application to the FDA for LYMPHIR™, aimed at treating adults with relapsed or refractory cutaneous T-cell lymphoma. This move signals a significant step forward for the company and holds promise for individuals affected by this challenging condition.

For further insights into CTXR stock, check out TipRanks’ Stock Analysis page.

Looking for more investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Optimize your mobile reading experience. Download the TipRanks App today!